130773-02-3

基本信息
盐酸奈康唑
盐酸奈替康唑
(E)-1-(2-(甲硫基)-1-(2-(戊氧基)苯基)乙烯基)-1H-咪唑盐酸盐
Atolant
Neticonazole hydrochloride
1-[2-methylsulfanyl-1-(2-pentoxyphenyl)ethenyl]imidazole hydrochloride
1-[(E)-2-methylsulfanyl-1-(2-pentoxyphenyl)ethenyl]imidazole,hydrochloride
(E)-1-(2-(Methylthio)-1-(2-(pentyloxy)phenyl)vinyl)-1H-imidazole hydrochloride
long-acting,colorectal,Neticonazole,antifungal,Neticonazole Hydrochloride,Imidazole,anti-cancer,nSMase2,Fungal,secretion,Inhibitor,p-ERK,anti-infection,inhibit,exosome
制备方法

628-17-1
![(E)-1-[2-甲巯基-1-[2-羟基苯基]乙烯基]-1H-咪唑](/CAS/20180629/GIF/138206-46-9.gif)
138206-46-9

130773-02-3
以1-碘戊烷和(E)-1-[2-甲巯基-1-[2-羟基苯基]乙烯基]-1H-咪唑为原料,合成(E)-1-(2-(甲硫基)-1-(2-(戊氧基)苯基)乙烯基)-1H-咪唑盐酸盐的一般步骤如下:将式(4)化合物(E)-1-[1-(2-羟基苯基)-2-(甲硫基)乙烯基]-1H-咪唑(15.1 g,65 mmol)、氢氧化钾(5.1 g,91 mmol)和1-碘戊烷(15.55 g,78 mmol)溶于75 mL DMF中,室温搅拌反应3.5小时。反应完成后,将反应液倒入375 mL水中,用乙酸乙酯萃取,有机相依次用水和饱和食盐水洗涤。减压浓缩有机相,得到油状物。将该油状物溶于氯化氢气体饱和的乙酸乙酯中,搅拌10小时。反应液中析出白色固体,经过滤,用乙腈洗涤,真空干燥,得到16.4 g白色固体产物。产率:73.2%。HPLC纯度(面积归一化法):99.61%,单一杂质含量<0.1%。
参考文献:
[1] Patent: CN107556245, 2018, A. Location in patent: Paragraph 0045; 0046
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/05/22 | HY-128365 | 盐酸奈替康唑 Neticonazole hydrochloride | 130773-02-3 | 25mg | 650元 |
2025/05/22 | HY-128365 | 盐酸奈替康唑 Neticonazole hydrochloride | 130773-02-3 | 10 mM * 1 mLin DMSO | 715元 |
2025/05/22 | HY-128365 | 盐酸奈替康唑 Neticonazole hydrochloride | 130773-02-3 | 50mg | 950元 |
常见问题列表
Fungal
Neticonazole (10 µM; 48 hours; C4-2B cells) treatment decreases the levels of both Alix and Rab27a, and significantly decreases nSMase2 levels. Neticonazole causes a significant inhibition in p-ERK levels.
Neticonazole (0-10 µM) exhibits a potent and dose-dependent inhibition of exosome release from C4-2B cells.
Neticonazole hydrochloride is also an orally active exosome biogenesis and secretion inhibitor.
Western Blot Analysis
Cell Line: | C4-2B cells |
Concentration: | 10 µM |
Incubation Time: | 48 hours |
Result: | Decreased the levels of both Alix and Rab27a, and significantly decreased nSMase2 levels. |
Neticonazole (1-100 ng/kg; oral gavage; daily; for 15 days; male C57BL/6 mice) treatment significantly improves the survival of intestinal dysbacteriosis (IDB) mice with colorectal cancer (CRC) xenograft tumors, likely through increasing apoptosis of CRC xenograft tumor cells.
Animal Model: | Male C57BL/6 mice (8 weeks old) given ampicillin, neomycin, metronidazole and vancomycin, and injected with SW480 cells |
Dosage: | 1 ng/kg, 10 ng/kg and 100 ng/kg |
Administration: | Oral gavage; daily; for 15 days |
Result: | Significantly improved the survival of IDB mice with CRC xenograft tumors. |